The Multi Luminance Mobility Test (MLMT) was used as a primary outcome measure in the landmark clinical trial of voretigene neparvovec (Luxturna) for RPE65-related Leber’s congenital amaurosis, the first approved gene therapy in ophthalmology.19 Here, RPE65 is linked to Leber congenital amaurosis.